54564
document
Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients . Osteopontin ( OPN ) is a glycoprotein that is secreted by osteoblasts and hematopoietic cells . OPN suppresses the proliferation of hematopoietic stem cells in vitro and may regulate the hematopoietic stem cell pool . Increased serum OPN concentrations occur in chronic myeloid leukemia , multiple myeloma , and acute myeloid leukemia ( AML ) . In the present study , we analyzed the prognostic impact of OPN in AML by investigating the expression and relevance of OPN in newly diagnosed AML patients from 2 large study groups ( the German AML Cooperative Group and the Dutch-Belgian Hematology Oncology Cooperative group ) . IHC ( n = 84 ) , ELISAs of blood/BM sera ( n = 41 ) , and microarray data for mRNA levels ( n = 261 ) were performed . Expression of OPN protein was increased in AML patients both in BM blasts ( IHC ) and in BM serum ( ELISA ) compared with healthy controls . Patients expressing high levels of OPN within the BM ( IHC ) experienced shortened overall survival ( OS ; P = .025 ) . Multivariate analysis identified karyotype , blast clearance ( day 16 ) , and the level of OPN expression as independent prognostic factors for OS . This prompted us to analyze microarray data from 261 patients from a third cohort . The analysis confirmed OPN as a prognostic marker . In summary , high OPN mRNA expression indicated decreased event-free survival ( P = .0002 ) and OS ( P = .001 ) . The prognostic role of OPN was most prominent in intermediate-risk AML . These data provide evidence that OPN expression is an independent prognostic factor in AML .
54565
Intervention_Pharmacological
Osteopontin
54566
Intervention_Pharmacological
Osteopontin
54567
Intervention_Pharmacological
OPN
54568
Intervention_Pharmacological
OPN
54569
Intervention_Pharmacological
ELISAs
54570
Intervention_Pharmacological
microarray data for mRNA levels
54571
Intervention_Pharmacological
OPN
54572
Intervention_Pharmacological
IHC
54573
Intervention_Pharmacological
ELISA
54574
Intervention_Pharmacological
OPN
54575
Intervention_Pharmacological
OPN
54576
Intervention_Pharmacological
OPN
54577
Intervention_Pharmacological
OPN
54578
Outcome_Mortality
survival
54579
Outcome_Physical
Osteopontin ( OPN )
54580
Outcome_Physical
expression and relevance of OPN
54581
Outcome_Physical
IHC
54582
Outcome_Physical
Expression of OPN protein
54583
Outcome_Physical
levels of OPN within the BM
54584
Outcome_Mortality
overall survival
54585
Outcome_Physical
level of OPN expression
54586
Outcome_Mortality
OS
54587
Outcome_Physical
OPN mRNA expression
54588
Outcome_Mortality
event-free survival
54589
Outcome_Physical
OPN expression
54590
Participant_Condition
acute myeloid leukemia patients .
54591
Participant_Sample-size
2
54592
Participant_Sample-size
261 patients from a third cohort